Evaluation of the Correlation between Coronary Artery Disease and Nonalcoholic Fatty Liver Disease: Is There Any Correlation?
-
Zahra Momayez Sanat
,
Seyyed Mojtaba Ghorashi
,
Ava Ajir
,
Amir Fazeli
,
Hamidreza Hekmat
,
Negar Omidi
Abstract
Background: Coronary artery disease (CAD) and nonalcoholic fatty liver disease (NAFLD) are 2 common diseases around the globe. This investigation aimed to evaluate NAFLD prevalence in patients with CAD and the potential association between NAFLD and CAD.
Methods: This case-control study was performed between January 2017 and January 2018 at Ziaeian Hospital, Tehran, Iran. All patients aged between 35 and 5 years and referred for myocardial perfusion imaging were selected for the study. Totally, 180 participants were divided into CAD+ and CAD− groups. CAD was defined as stenosis of greater than 50.0% in at least 1 coronary artery. Afterward, all the patients underwent abdominal sonography and laboratory tests for NAFLD evaluation. Patients with a history of liver diseases, alcohol consumption, and drug-induced steatosis were excluded.
Results: The study population consisted of 122 women (67.8%) and 58 men (32.2%) at a mean age of 49.31±5.42 years. NAFLD was detected in 115 patients. NAFLD prevalence in the CAD+ group was 78.9%. NAFLD was determined as an independent risk factor for CAD (OR, 3.9).
Conclusion: NAFLD prevalence was high in the CAD+ group. The incidence of steatosis is on the rise in the general population. Hence, considering the high prevalence of abdominal obesity, all patients with NAFLD should be evaluated for CAD.
1. Patil R, Sood GK. Non-alcoholic fatty liver disease and cardiovascular risk. World J Gastrointest Pathophysiol 2017;8:51-58.
2. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007;191:235-240.
3. Naderian M, Ebrahimi H, Sohrabpour AA. Prevalence of nonalcoholic fatty liver disease in the middle eastern area: What is the exact estimation? Hepatology 2016;64:1390-1391.
4. Temple JL, Cordero P, Li J, Nguyen V, Oben JA. A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. Int J Mol Sci 2016;17:947.
5. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007;11:1-16.
6. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-379.
7. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-285.
8. Federico A, Dallio M, Masarone M, Persico M, Loguercio C. The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction. Eur Rev Med Pharmacol Sci 2016;20:4731-4741.
9. Gudbjartsson T, Andersen K, Danielsen R, Geirsson A, Thorgeirsson G. Yfirlitsgrein um kransæðasjúkdóm - fyrri hluti: faraldsfræði, meingerð, einkenni og rannsóknir til greiningar [Review on coronary artery disease - part I: epidemiology, pathophysiology, clinical presentation and work-up]. Laeknabladid 2014;100:667-676.
10. Park GM, Yun SC, Cho YR, Gil EH, Her SH, Kim SH, Jo MW, Lee MS, Lee SW, Kim YH, Yang DH, Kang JW, Lim TH, Kim BJ, Koh JM, Kim HK, Choe J, Park SW, Park SJ. Prevalence of coronary atherosclerosis in an Asian population: findings from coronary computed tomographic angiography. Int J Cardiovasc Imaging 2015;31:659-668.
11. No authors listed. Executive summary: Standards of medical care in diabetes--2013. Diabetes Care. 2013 Jan;36 Suppl 1(Suppl 1):S4-10.
12. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021-3104.
13. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
14. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995;854:1-452.
15. Farkouh ME, Boden WE, Bittner V, Muratov V, Hartigan P, Ogdie M, Bertolet M, Mathewkutty S, Teo K, Maron DJ, Sethi SS, Domanski M, Frye RL, Fuster V. Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol 2013;61:1607-1615.
16. Fotbolcu H, Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol 2016;22:4079-4090.
17. Friedrich-Rust M, Schoelzel F, Maier S, Seeger F, Rey J, Fichtlscherer S, Herrmann E, Zeuzem S, Bojunga J. Severity of coronary artery disease is associated with non-alcoholic fatty liver dis-ease: A single-blinded prospective mono-center study. PLoS One 2017;12:e0186720.
18. Friedrich-Rust M, Schoelzel F, Maier S, Seeger F, Rey J, Fichtlscherer S, Herrmann E, Zeuzem S, Bojunga J. Severity of coronary artery disease is associated with non-alcoholic fatty liver dis-ease: A single-blinded prospective mono-center study. PLoS One 2017;12:e0186720.
19. Alper AT, Hasdemir H, Sahin S, Ontürk E, Akyol A, Nurkalem Z, Cakmak N, Erdinler I, Gürkan K. The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome. Turk Kardiyol Dern Ars 2008;36:376-381.
20. Rabiee B, Roozafzai F, Hemasi GR, Poustchi H, Keyvani H, Khonsari MR, Ajdarkosh H, Maadi M, Sima Saeedian F, Zamani F. The Prevalence of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus in an Iranian Population. Middle East J Dig Dis 2017;9:86-93.
21. Moghaddasifar I, Lankarani KB, Moosazadeh M, Afshari M, Ghaemi A, Aliramezany M, Afsar Gharebagh R, Malary M. Prevalence of Non-alcoholic Fatty Liver Disease and Its Related Factors in Iran. Int J Organ Transplant Med 2016;7:149-160.
22. Baharvand-Ahmadi B, Sharifi K, Namdari M. Prevalence of non-alcoholic fatty liver disease in patients with coronary artery disease. ARYA Atheroscler 2016;12:201-205.
23. Wong VW, Wong GL, Yip GW, Lo AO, Limquiaco J, Chu WC, Chim AM, Yu CM, Yu J, Chan FK, Sung JJ, Chan HL. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011;60:1721-1727.
24. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006;22:437-443.
25. Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, Kakafika AI, Tziomalos K, Burroughs AK, Elisaf MS. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006;22:873-883.
2. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007;191:235-240.
3. Naderian M, Ebrahimi H, Sohrabpour AA. Prevalence of nonalcoholic fatty liver disease in the middle eastern area: What is the exact estimation? Hepatology 2016;64:1390-1391.
4. Temple JL, Cordero P, Li J, Nguyen V, Oben JA. A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. Int J Mol Sci 2016;17:947.
5. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007;11:1-16.
6. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-379.
7. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-285.
8. Federico A, Dallio M, Masarone M, Persico M, Loguercio C. The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction. Eur Rev Med Pharmacol Sci 2016;20:4731-4741.
9. Gudbjartsson T, Andersen K, Danielsen R, Geirsson A, Thorgeirsson G. Yfirlitsgrein um kransæðasjúkdóm - fyrri hluti: faraldsfræði, meingerð, einkenni og rannsóknir til greiningar [Review on coronary artery disease - part I: epidemiology, pathophysiology, clinical presentation and work-up]. Laeknabladid 2014;100:667-676.
10. Park GM, Yun SC, Cho YR, Gil EH, Her SH, Kim SH, Jo MW, Lee MS, Lee SW, Kim YH, Yang DH, Kang JW, Lim TH, Kim BJ, Koh JM, Kim HK, Choe J, Park SW, Park SJ. Prevalence of coronary atherosclerosis in an Asian population: findings from coronary computed tomographic angiography. Int J Cardiovasc Imaging 2015;31:659-668.
11. No authors listed. Executive summary: Standards of medical care in diabetes--2013. Diabetes Care. 2013 Jan;36 Suppl 1(Suppl 1):S4-10.
12. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021-3104.
13. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
14. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995;854:1-452.
15. Farkouh ME, Boden WE, Bittner V, Muratov V, Hartigan P, Ogdie M, Bertolet M, Mathewkutty S, Teo K, Maron DJ, Sethi SS, Domanski M, Frye RL, Fuster V. Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol 2013;61:1607-1615.
16. Fotbolcu H, Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol 2016;22:4079-4090.
17. Friedrich-Rust M, Schoelzel F, Maier S, Seeger F, Rey J, Fichtlscherer S, Herrmann E, Zeuzem S, Bojunga J. Severity of coronary artery disease is associated with non-alcoholic fatty liver dis-ease: A single-blinded prospective mono-center study. PLoS One 2017;12:e0186720.
18. Friedrich-Rust M, Schoelzel F, Maier S, Seeger F, Rey J, Fichtlscherer S, Herrmann E, Zeuzem S, Bojunga J. Severity of coronary artery disease is associated with non-alcoholic fatty liver dis-ease: A single-blinded prospective mono-center study. PLoS One 2017;12:e0186720.
19. Alper AT, Hasdemir H, Sahin S, Ontürk E, Akyol A, Nurkalem Z, Cakmak N, Erdinler I, Gürkan K. The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome. Turk Kardiyol Dern Ars 2008;36:376-381.
20. Rabiee B, Roozafzai F, Hemasi GR, Poustchi H, Keyvani H, Khonsari MR, Ajdarkosh H, Maadi M, Sima Saeedian F, Zamani F. The Prevalence of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus in an Iranian Population. Middle East J Dig Dis 2017;9:86-93.
21. Moghaddasifar I, Lankarani KB, Moosazadeh M, Afshari M, Ghaemi A, Aliramezany M, Afsar Gharebagh R, Malary M. Prevalence of Non-alcoholic Fatty Liver Disease and Its Related Factors in Iran. Int J Organ Transplant Med 2016;7:149-160.
22. Baharvand-Ahmadi B, Sharifi K, Namdari M. Prevalence of non-alcoholic fatty liver disease in patients with coronary artery disease. ARYA Atheroscler 2016;12:201-205.
23. Wong VW, Wong GL, Yip GW, Lo AO, Limquiaco J, Chu WC, Chim AM, Yu CM, Yu J, Chan FK, Sung JJ, Chan HL. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011;60:1721-1727.
24. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006;22:437-443.
25. Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, Kakafika AI, Tziomalos K, Burroughs AK, Elisaf MS. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006;22:873-883.
| Files | ||
| Issue | Vol 18 No 1 (2023): J Teh Univ Heart Ctr | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/jthc.v18i1.12576 | |
| Keywords | ||
| Myocardial perfusion imaging Adverse effects Coronary artery disease Nonalcoholic fatty liver disease | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Momayez Sanat Z, Ghorashi SM, Ajir A, Fazeli A, Hekmat H, Omidi N. Evaluation of the Correlation between Coronary Artery Disease and Nonalcoholic Fatty Liver Disease: Is There Any Correlation?. J Tehran Heart Cent. 2023;18(1):10-15.
